Your browser is no longer supported. Please, upgrade your browser.
Settings
GLMD Galmed Pharmaceuticals Ltd. daily Stock Chart
GLMD [NASD]
Galmed Pharmaceuticals Ltd.
Index- P/E- EPS (ttm)-1.09 Insider Own21.36% Shs Outstand21.15M Perf Week-6.00%
Market Cap100.52M Forward P/E- EPS next Y-1.52 Insider Trans0.00% Shs Float16.58M Perf Month-11.50%
Income-23.00M PEG- EPS next Q-0.32 Inst Own35.20% Short Float2.81% Perf Quarter23.37%
Sales- P/S- EPS this Y-78.30% Inst Trans- Short Ratio6.67 Perf Half Y-31.52%
Book/sh3.03 P/B1.50 EPS next Y-15.30% ROA-29.30% Target Price- Perf Year-29.94%
Cash/sh3.11 P/C1.46 EPS next 5Y20.00% ROE-31.50% 52W Range3.02 - 7.38 Perf YTD-21.45%
Dividend- P/FCF- EPS past 5Y-1.90% ROI- 52W High-38.48% Beta2.52
Dividend %- Quick Ratio11.60 Sales past 5Y- Gross Margin- 52W Low50.33% ATR0.29
Employees17 Current Ratio11.60 Sales Q/Q- Oper. Margin- RSI (14)40.94 Volatility4.63% 5.79%
OptionableYes Debt/Eq0.00 EPS Q/Q-73.10% Profit Margin- Rel Volume1.13 Prev Close4.76
ShortableYes LT Debt/Eq0.00 EarningsMay 14 BMO Payout- Avg Volume69.83K Price4.54
Recom1.90 SMA20-8.41% SMA50-8.16% SMA200-7.47% Volume79,019 Change-4.62%
May-22-20Downgrade B. Riley FBR Buy → Neutral $11 → $8
Feb-04-20Initiated Craig Hallum Buy $18
Jan-30-20Resumed Cantor Fitzgerald Overweight $9 → $14
Dec-02-19Initiated Canaccord Genuity Buy
Dec-12-18Initiated B. Riley FBR Buy $28
Aug-02-18Reiterated Maxim Group Buy $30 → $27
Jul-13-18Initiated Stifel Buy $35
Jul-12-18Initiated Cantor Fitzgerald Overweight $59
Jun-12-18Reiterated H.C. Wainwright Buy $24 → $43
Mar-15-18Upgrade Maxim Group Hold → Buy $14
Feb-14-18Downgrade Maxim Group Buy → Hold
Feb-12-18Reiterated H.C. Wainwright Buy $18 → $24
Nov-15-17Initiated ROTH Capital Buy $32
Aug-08-17Reiterated H.C. Wainwright Buy $12 → $18
Jul-31-17Reiterated Maxim Group Buy $9 → $14
Aug-01-16Reiterated Maxim Group Buy $24 → $9
Jul-06-16Resumed ROTH Capital Buy $6
Mar-28-16Resumed H.C. Wainwright Buy $22
Jun-23-15Initiated H.C. Wainwright Buy $21
May-06-15Initiated Sun Trust Rbsn Humphrey Buy $20
Jul-06-20 07:55AM  
Jun-26-20 06:42AM  
Jun-10-20 08:34AM  
May-14-20 05:31PM  
07:00AM  
May-07-20 08:30AM  
May-02-20 09:36AM  
Mar-26-20 09:40PM  
Mar-12-20 07:00AM  
Mar-05-20 08:30AM  
Feb-28-20 09:30AM  
Feb-05-20 04:11PM  
Jan-03-20 08:25AM  
Dec-14-19 07:21PM  
Dec-04-19 09:26AM  
Nov-29-19 08:41AM  
Nov-08-19 10:57PM  
Nov-06-19 07:00AM  
Nov-04-19 09:10AM  
Oct-31-19 08:30AM  
Oct-30-19 08:30AM  
Sep-26-19 08:00AM  
Sep-19-19 01:05PM  
Aug-12-19 04:33AM  
Aug-05-19 07:00AM  
Jul-29-19 08:30AM  
Jul-24-19 01:17PM  
May-23-19 12:37PM  
May-07-19 08:25AM  
07:21AM  
07:00AM  
Apr-30-19 08:30AM  
Apr-09-19 07:30AM  
Mar-13-19 08:25AM  
07:00AM  
Mar-12-19 10:02AM  
08:00AM  
Mar-06-19 08:30AM  
Dec-28-18 04:52PM  
Dec-12-18 02:26PM  
Dec-11-18 09:22AM  
Nov-20-18 08:45AM  
Nov-14-18 07:50AM  
Nov-13-18 11:30AM  
04:02AM  
Nov-05-18 08:45AM  
07:39AM  
07:00AM  
Oct-31-18 03:38PM  
Oct-29-18 08:30AM  
Oct-12-18 03:21PM  
Oct-02-18 08:39AM  
Sep-27-18 08:00AM  
Aug-02-18 05:40PM  
10:55AM  
09:51AM  
07:00AM  
Jul-26-18 08:30AM  
Jul-20-18 11:42AM  
11:26AM  
Jul-13-18 07:02PM  
10:49AM  
08:00AM  
Jul-12-18 12:11PM  
08:00AM  
Jun-26-18 07:06AM  
Jun-25-18 07:30AM  
Jun-20-18 08:36AM  
Jun-19-18 09:37PM  
Jun-18-18 06:30AM  
Jun-16-18 07:18AM  
Jun-15-18 09:27AM  
08:07AM  
07:40AM  
Jun-14-18 10:30AM  
09:23AM  
Jun-13-18 09:43AM  
08:15AM  
08:00AM  
Jun-12-18 12:37PM  
11:23AM  
10:37AM  
08:47AM  
08:36AM  
08:15AM  
07:00AM  
Jun-11-18 04:30PM  
May-14-18 10:11AM  
May-11-18 05:31PM  
May-09-18 07:21AM  
07:00AM  
May-02-18 08:18PM  
May-01-18 08:00AM  
Apr-20-18 05:06PM  
Apr-16-18 07:00AM  
Apr-11-18 08:00AM  
Apr-03-18 07:00AM  
Mar-27-18 07:00AM  
Mar-15-18 01:12PM  
Mar-13-18 07:30AM  
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.